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ABSTRACT: In a randomized controlled study, we investigated the effect of treatment with intravenous
neridronate in prepubertal children with OI. Our study suggests that quarterly intravenous infusions of the
bisphosphonate significantly raise the rate of increase in BMD at both the spine and hip, the projected area
of the lumbar vertebrae, and height. These results are associated with a significant decrease in the risk of
clinical fractures.
Introduction: Osteogenesis imperfecta (OI) is a heritable disease of connective tissue, characterized by in-
creased bone fragility. Bisphosphonates currently seem to be the most promising therapy, but randomized,
controlled studies are scarce and have never been carried out in prepubertal children.
Materials and Methods: This was a randomized, controlled 3-year clinical trial. The Italian Patients’ Society
of OI (AsItOI) sent their members affected by any type of OI to two centers at the University of Verona
(Italy) to participate in the study. Sixty-four children, 6–11 years of age for boys and 6–9 years of age for girls,
with no signs of puberty and who were never treated with bisphosphonates, were randomized to either
intravenous neridronate (2 mg/kg infused IV in 30 minutes every 3 months) or no treatment, with a ratio of
2:1. Control patients were given the same bisphosphonate therapy at the end of the first year. BMD and
projected bone areas, as measured by DXA, at spine and hip, height, and peripheral fracture incidence, both
prospective and retrospective (2 years preceding randomization), were the main outcomes of the study.
Results: At the end of the first year, spine and hip BMD rose by 3.5–5.7% in control patients and by 18–25%
(p < 0.001 versus controls) in the active group, respectively. During the following 2 years, the treatment in all
patients was associated with BMD increases of 10–25% per year. Height and the DXA-derived projected area
of lumbar spine rose during the first year of observation significantly more in the active group than in the
control group (<0.01 and <0.05, respectively). Both height and spine projected area continued to rise in the
treated patients toward levels found in healthy individuals. During the first year of treatment, 45% of the
control patients and 27% of the active group had a nonvertebral fracture, but this difference was not statis-
tically significant (p 0.2). The total number of fractures was 18 in the 22 control patients and 13 in the active
group (relative risk, 0.36; 95% CI, 0.15–0.87; p < 0.05).
Conclusion: Intravenous neridronate infusions, administered quarterly, significantly increase BMD and lower
the risk of clinical fracture in prepubertal children with OI.
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INTRODUCTION
OSTEOGENESIS IMPERFECTA (OI) is a heritable disease ofconnective tissue caused by heterologous mutations in
the genes encoding for type I collagen and characterized by
increased bone fragility. Four types are commonly distin-
guished on the basis of clinical and genetic features, al-
though overlap forms are often observed. In its mildest
form (type I), fractures tend to occur mostly before puberty
and again after menopause. Type II OI leads to perinatal
death. Type III OI causes fractures that are very frequent,
resulting in short stature, severe deformities, and shortened
life expectancy. These fractures are also typical of type IV,
but are less severe. The clinical expression of the disease is
not always typical; this led to the identification of at least
another three types of OI.(1)
New potentially ultimate therapies have been proposed
for the treatment of OI,(2) but to date, bisphosphonates
seem to be the most promising therapy both in adults(3) and
in children.(4–12) The initial beneficial effect reported in a
number of small studies has been recently supported in a
larger cohort of children treated for up to 5 years with
cyclical intravenous pamidronate.(6,8) This treatment re-
sulted in clinically meaningful increases in BMD by DXAThe authors have no conflict of interest.
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at any studied skeletal site. More recently, in a 2-year ran-
domized controlled trial, it was reported that oral daily ol-
padronate treatment results in a reduction of fracture risk
of long bones in children with OI.(13) In 1995, in collabora-
tion with the “Istituto Superiore di Sanità” (part of the
Ministry of Health), the Italian Association of Patients with
OI (AsItOI) initiated a large randomized, controlled thera-
peutical trial of intravenous neridronate in both children
and adult patients with OI. We have recently reported the
results obtained in men and in premenopausal women.
Here, we report the results observed in prepubertal chil-
dren. Neridronate is an amino-bisphosphonate structurally
similar to alendronate and pamidronate, differing only in
the number of methyl groups of the side-chain: five for
neridronate, three for alendronate, and two for pamidro-
nate.(14) It has been studied for the treatment of Paget’s
disease of bone(15–18) and recently registered in Italy for the
treatment of OI on the basis of the clinical trials reported in
the past and here.
MATERIALS AND METHODS
Patients
All subjects affected by any type of OI and registered
with the AsItOI were informed by the association newslet-
ter, either directly or through their parents, regarding the
possibility to participate in a clinical trial of a new bisphos-
phonate.(3) Several other patients contacted our center af-
ter a public appeal on national radio.
After excluding the patients who had already received
bisphosphonates or were <3 years of age, informed written
consent was obtained from 219 patients (Fig. 1).
After the publication of the papers from the Montreal
group,(6,8) one-half of the new patients refused their con-
sent to be randomized into the trial. They were treated with
the same dose of neridronate, and the observed results will
be analyzed separately. The recruitment ended in January
2001. Interestingly, none of the patients who initially gave
their consent withdrew from the study. Eligible OI patients
were separated into four groups: infants, children, and peri-
pubertal and adults. The interim analysis of adult patients
has been reported elsewhere.(3) Here we report the results
observed in the 64 prepubertal children with any type of OI,
age ranging from 6 to 11 years of age in boys and 6–9 years
of age in girls, with no signs of puberty.
The principal characteristics of the 64 patients are listed
in Table 1. The history of prior clinical nonvertebral frac-
ture during 2 years preceding recruitment was carefully col-
lected from all patients.
Treatment
The patients were randomized according to OI type (type
I or type III and IV) to either intravenous (active group) or
no treatment (control group), with a ratio of 2:1. Neridro-
nate (2 mg/kg body weight) diluted in 250 ml of saline so-
lution was infused intravenously in 30 minutes every 3
months. All patients had their dietary calcium intake regu-
larly evaluated and maintained, through diet or supplemen-
tation, above 600–800 and 1000 mg daily according to their
age: <7, 7–10, >0 years of age, respectively. Vitamin D2
supplements (50,000 units monthly) were given if the serum
25(OH)vitamin D levels fell below 20 ng/ml. Calcium and/
or vitamin D2 supplements were necessary throughout the
study in only four patients. It is worth noting that all pa-
tients had adequate calcium and vitamin D intake for years
because of the continuous educational program from
AsItOI.
The control patients commenced the neridronate therapy
after 12 months of follow-up with continued controlled cal-
cium and vitamin D intake.
FIG. 1. Trial profile.
TABLE 1. PRINCIPAL CLINICAL AND ANAGRAPHIC
CHARACTERISTICS (MEANS ± SD) OF STUDY POPULATION AT
THE BEGINNING OF THE PROSPECTIVE OBSERVATION
Control group Active group
Patients (N) 22 42
Type of OI (I-III-IV) 14-2-6 28-2-12
Sex (Male-Female) 13-9 20-22
Age (years; mean ± SD) 8.6 ± 2.4 9.0 ± 2.3
Weight (kg, mean ± SD) 27.8 ± 14.6 29.2 ± 12.1
Height (cm, mean ± SD) 120.8 ± 23.7 123.0 ± 22.0
Lumbar spine BMD (mg/cm2) 356 ± 165 407 ± 178
Femoral neck BMD (mg/cm2) 422 ± 221 481 ± 162
Total hip BMD (mg/cm2) 508 ± 216 519 ± 190
Total alkaline phosphatase (U/I) 281 ± 77 298 ± 66
Bone alkaline phosphatase (U/I) 122 ± 31 130 ± 27
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Study protocol was approved and constantly monitored
by the local ethical committee and the Istituto Superiore
della Sanità (part of the Italian Ministry of Health).
Measurements
All patients were seen at 3-month intervals, but full clini-
cal evaluation, including bone densitometry measurements
by DXA and fasting serum and urinary (second morning
voiding) biochemistry, was obtained per-protocol every 6
months before the infusion of neridronate. Routine bio-
chemistry, including serum calcium, phosphate, creatinine,
and total and bone alkaline phosphatase, were carried out
on the same day of sample collection. Aliquots of both
serum and urines were stored at −20°C for future evalua-
tion of bone markers. The general practitioners of all pa-
tients were also asked to evaluate albumin-adjusted serum
calcium at the appearance of symptoms even vaguely re-
lated to hypocalcemia. Routine biochemistry was measured
by standard autoanalyzer procedures and serum bone alka-
line phosphatase by a commercial kit (Bone AP: Alkphase–
B; Metra-Biosystems, Mountain View, CA, USA) with an
interassay CV of 9%.
Radiographs of the spine (antero-posterior and lateral
views) were obtained at baseline and after 12 and 36
months, but the best approach for analyzing the changes in
shape of the vertebrae is still under evaluation. Additional
X-rays were obtained at any skeletal site whenever symp-
toms of fractures occurred. Changes in BMD and projected
area at the lumbar spine and total hip were measured by
DXA (QDR 4000; Hologic, Waltham, MA, USA). Appro-
priate DXA evaluations could not be obtained in 11% and
12% of the patients at the spine and hip, respectively, most
often because it was impossible to obtain correct position-
ing. The precision error for BMD at different skeletal sites
was assessed by double measurements at one of the time-
points of the study in all participants. The CV is somewhat
greater than that observed in adults, ranging from 1.4% to
2.9% at the spine and hip, respectively.
Height was obtained while patients were standing
(Harpender stadiometer), or if wheelchair-bound, lying on
the bed of the Hologic DXA instrument.
Statistical analysis
The within-subject changes in BMD were tested by two-
sided paired t-test, and the between-group differences were
tested by ANOVA and by Tukey test. These latter differ-
ences were also tested after adjustment for baseline BMD
values, type of OI, and sex (covariance analysis). Intention-
to-treat analysis was planned, but it was not applied be-
cause all patients completed the treatment follow-up. The
change in the rate of fracture incidence was analyzed by the
McNemar test (2 × 2; version 11; SPSS).
RESULTS
Before treatment, all subjects had normal serum calcium,
phosphate, 25(OH)vitamin D (>12 ng/ml), and PTH levels
(Allegro intact PTH, normal values < 60 pg/ml), and there
was no evidence of other relevant diseases. The two groups
of patients were somewhat different for age, sex distribu-
tion, weight, height, and baseline BMD values, but none of
these differences was statistically significant (Table 1). All
patients completed the planned period of observation and
treatment. None of the children developed signs of puberty
during the first year of observation. Four patients in the
control group and seven in the active group showed signs of
puberty (stages 2 and 3) at the end of the third year of
observation.
The mean changes in BMD in the two groups are shown
in Fig. 2. In the control group, spine and hip BMDs rose
significantly (p < 0.01) by 3.5–5.7% (Fig. 1) during the first
year without active treatment. The treatment in both
groups was associated with BMD changes at the spine of
∼30% during the first year, 20% during the second year,
and 15% during the third year of treatment. The corre-
sponding changes at the femoral neck and total hip were
18–25%, 13–15%, and 7–8%, respectively (all highly signifi-
cant versus both baseline and the previous year). Spine Z
score did not change in the control group during the first
year, but it rose gradually from −3.39 to −2.01 (p < 0.001) in
the active group over 3 years.
During the first year, the projected area of lumbar spine
rose by 2.0% in the control group, which is significantly
lower than the 6.7% increase observed in treated patients
(Table 2). In the subsequent 2 years, the projected spine
area rose by 14%.
The mean individual height rose by 0.9% and 2.6% dur-
FIG. 2. BMD changes during treatment with intravenous neridro-
nate (solid line) and no-treatment periods (dashed line) in the
active (diamonds) and control (open circle) group. (°p < 0.05
between groups; *p < 0.05 vs. baseline in the control group; at all
the other time-points, the changes were significantly different
from zero at p < 0.001).
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ing the first year in the control and active groups, respec-
tively (p < 0.01). The rate of height increase was maintained
during the second and third year, with an apparent catch-up
to the values found in healthy subjects of the same age (data
not shown). There were no differences in the BMD, pro-
jected area, and height increments between boys and girls
or among OI types, and the increments were not related to
initial age or pubertal stage at the end of the study. The
densitometric and height values and their changes during
follow-up remained substantially identical after adjustment
for baseline BMD values, sex, and OI type.
Both total and bone alkaline phosphatase progressively
declined during treatment (Fig. 3). A significant decrease
was observed also during the control year.
Over the 5 years of evaluation (2 retrospective and 3
prospective years), all patients had at least one fracture at
the lower and/or upper limbs. Nine patients had fractures at
the ribs, scapula, and clavicle.
The numbers of nonvertebral fractures during the entire
period of evaluation are listed in Table 3. During the first
year of observation, 45% of the patients of control group
and 27% of the active group had at least one fracture (ad-
justed relative risk [RR]  0.60; 95% CI, 0.21–1.59). The
treated patients who fractured experienced most often a
single fracture (Table 4), and the overall number of frac-
tures was significantly lower in the active than in the control
group: 13 in 44 patients and 18 in 22 patients, respectively
(RR 0.36; 95% CI, 0.15–0.87; p < 0.05). A slight further
decrease in the RR of fracture was observed for values
adjusted for initial BMD, OI type, and sex (RR  0.33;
95% CI, 0.15–0.82; p < 0.02).
During the >150 patient-years during a pooled no-
treatment period (prerecruitment and control time), 88
(59%) had 285 fractures (mostly multiple during the same
traumatic event), whereas the incidence during treatment
was 20% (34 of the 170 patient-years had 71 fractures; RR
for number of fractured patients 0.34; 95% CI, 0.22–0.54; p
> 0.001; RR for global number of fractures 0.18; 95% CI,
0.13–0.29; p < 0.001; Tables 3 and 4).
Ten of the patients complained of flu-like symptoms, re-
sembling a typical acute phase reaction,(19) 24–36 h after
the first intravenous infusion, which lasted <36 h. An at-
tenuated response was also noted by all of them after the
second infusion. None of the patients complained of other
typical side effects associated with intravenous amino-
bisphosphonate administration.(20) Serum calcium and
phosphate were within the normal range at all time-points
before the neridronate infusions. Symptomatic hypocalce-
mia was never reported. Serum calcium was measured 3–7
days after the infusion, 19 times in 16 patients, with values
ranging from 8.1 to 9.2 mg/dl (normal range, 8.5–10.2 mg/
dl).
DISCUSSION
Bone fragility in OI results from quantitative and quali-
tative alterations in type I collagen that are not expected to
benefit directly from a treatment with antiresorbing agents,
such as bisphosphonates. However, there is histomorpho-
TABLE 2. PERCENT CHANGES (MEANS ± SD) IN HEIGHT AND DXA-DERIVED ANTERO-POSTERIOR PROJECTED AREA OF LUMBAR
SPINE AND NUMBER OF PATIENTS IN WHOM PUBERTAL STAGE ROSE FROM INITIAL 1 TO EITHER 2 OR 3 DURING YEARS 1 AND 2–3
Time (months)
Control group
(n = 22)
Active group
(n = 42)
Between-group
p†
0–12 Height 0.92 ± 1.08%* 2.64 ± 2.50%* <0.01
Spine area 1.97 ± 3.25% 6.68 ± 8.05%* <0.05
Tanner >1 0 0
12–36 Height 4.12 ± 4.11%* 3.88 ± 3.51%*
Spine area 14.18 ± 4.24%* 12.87 ± 5.99%*
Tanner >1 4 7
* p < 0.01 vs. zero.
† For values adjusted for baseline BMD, sex, and OI type.
FIG. 3. Changes in total and bone alkaline phosphatase during
treatment with intravenous neridronate (solid line) and no-
treatment periods (dashed line) in the active (diamonds) and con-
trol (open circle) group. With the exception of the 6-month time-
point in the control group, the changes at all time-points were
significantly different from zero at p < 0.01.
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metric and biochemical evidence of increased bone resorp-
tion in OI.(21–23) The high bone turnover might be caused
by recurrent fractures or be directly related to the abnormal
bone structure, but it might also contribute to further bone
loss and fragility. This provides a reasonable rationale for
the use of antiresorptive agents for the treatment of OI. In
fact, bisphosphonates are now the most frequently reported
therapeutic regimens for OI. The majority of the studies
with bisphosphonates were uncontrolled, but recently, two
randomized clinical trials have been reported, one, as part
of this study, in adults with intravenous intermittent
neridronate,(3) and another in children with oral daily ol-
padronate.(13)
In all these studies, it seems that the beneficial effects in
terms of DXA outcomes are associated with some evidence
of reduction in fracture risk.
Our original choice for intravenous infusion was influ-
enced by the fact that some children with the most severe
type of OI are either intolerant or incapable of following
recommendations for taking oral amino-bisphosphonates.
The dose of neridronate we adopted (2 mg/kg/3 months) is
somewhat comparable in terms of antiresorptive activity to
the widely used dose of intravenous pamidronate (9 mg/kg/
year).
Our results confirm the beneficial effects on BMD re-
ported in uncontrolled studies. However, the significant
BMD increases at all sites observed over 1 year in the con-
trol group emphasizes the need of controlled studies in
growing subjects for rare diseases such as OI. The correct
interpretation of the observed changes during neridronate
therapy in both total and bone alkaline phosphatase (Fig. 3)
remains partially uncertain. For example, the continuous
decrease in bone and total alkaline phosphatase is some-
what surprising given that, in postmenopausal osteoporosis
bone formation, parameters fall over 3–6 months and sta-
bilize with continuous treatment. In growing children, the
wide variation of changes related, in addition to treatment,
to pubertal development, should be taken into account. We
will hopefully be able to soon provide a clearer picture by
measuring a series of bone markers in a large number of
treated and untreated children with OI at the completion of
the trial.
The 64% reduction in fracture risk during the first year of
controlled observation is comparable with that observed in
the study with olpadronate in children. The controlled pe-
riod of our study is 1 year as opposed to the 2 years of the
oral olpadronate controlled study, but the overall length of
our study is greater (3 versus 2 years), and the number of
patients completing the study is double. At variance with
the olpadronate study, we decided to separately study pre-
pubertal and peripubertal children to avoid the effect of
puberty on both BMD changes and the clinical expression
of the disease itself. For this careful selection, we have been
able to show for the first time in a randomized, controlled
trial that bisphosphonate therapy may significantly increase
the rate of growth in height and in the projected area of
lumbar spine. The latter increase is likely to be caused, at
least in part, by increased mineralization of the outer profile
of the vertebral bodies over the density threshold for the
definition of the region of interest by DXA technology.
The good safety profile for intravenous therapy found in
adults(3) is confirmed in this study in children. None of the
patients complained of symptoms related to hypocalcemia,
although this would be more likely to occur in children than
in adults because of the higher bone turnover in children.
However, the long-term bone safety of bisphosphonate
therapy in growing subjects is still debated(24) for the po-
tential risk of osteomalacia(25) or even osteopetrosis.(26)
The correct degree of suppression of bone turnover is still
unclear, and further studies are needed to establish if the
dose and the duration of treatment should be tailored in-
dividually. It also remains to be assessed to what extent
bisphosphonate therapy changes the natural course of OI
for final height and skeletal deformities. We share these
cautions, but we are also aware that, for a rare and serious
TABLE 3. FRACTURE INCIDENCE DURING THE OBSERVATION TIME: NUMBER OF PATIENTS OR NUMBER OF EVENTS PER PATIENT-YEAR
Year
Control group (22 patients) Active group (42 patients)
Treatment
Fractured patients
[number (%)] No. of fractures Treatment
Fractured patients
[number (%)] No. of fractures
−2/−1 No 12 (54%) 22 No 24 (57%) 82
−1/0 No 18 (82%) 91 No 24 (57%) 72
0/1 No 10 (45%) 18 Yes 12 (27%) 13*
1/2 Yes 4 (18%) 11 Yes 5 (12%) 13
2/3 Yes 4 (18%) 9 Yes 9 (21%) 25
* Relative risk reduction 0.36 (CI, 0.15–0.87; p < 0.02).
TABLE 4. NUMBER OF FRACTURES OCCURRED PER
PATIENT-YEAR (PYR) DURING THE PROSPECTIVE STUDY AND
DURING THE OVERALL OBSERVATION PERIOD
Neridronate therapy
Fractures/
patient-year
Prospective controlled
observation (1 year)
Prospective + retrospective
observation (5 years)
No
(PYR
n = 22)
Yes
(PYR
n = 42)
No
(PYR
n = 150)
Yes
(PYR
n = 170)
0 54.5% 71.4% 41.3% 80.0%
1 22.7% 26.2% 11.3% 8.8%
2 13.6% 2.4% 25.3% 4.7%
3 9.1% 0% 22.0% 6.5%
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disease such as OI, the commitment for additional studies
should be accompanied by a less conservative approach in
using drugs with some evidence of efficacy. For this reason,
the AsItOI, on the basis of the results of our studies both in
children and adults, promoted and obtained the registration
of neridronate for the treatment of OI by the Italian health
authorities.
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